Why is Alector Stock (ALEC) 60% Higher Today?
Shares in U.S. biotech firm Alector ($ALEC) surged 60% in pre-market trading today after Swiss drugmaker Roche ($RHHBY) agreed to pay up to $1.27 b...
Alector Inc. (ALEC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 4,318,109 | $8,679,399 | +54% | 0.28% |
| 2. | Kynam Capital Derrick Tang | 3,808,494 | $7,655,073 | +91% | 0.42% |
| 3. | Balyasny Asset Management Dmitry Balyasny | 3,247,426 | $6,527,326 | +11% | 0.01% |
| 4. | 683 Capital Partners Ari Zweiman | 3,200,000 | $6,432,000 | 0.32% | |
| 5. | D E Shaw D. E. Shaw | 2,959,983 | $5,949,566 | -12% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.00 | 20,000 | $500,000.00 | 44,621 | 2020-02-03 | Filing | |
| $19.00 | 203,200 | $3,860,800.00 | 203,200 | 2019-02-11 | Filing | |
| $19.00 | 50,561 | $960,659.00 | 2,455,853 | 2019-02-11 | Filing | |
| $19.00 | 157,939 | $3,000,841.00 | 10,434,976 | 2019-02-11 | Filing | |
| $19.00 | 203,200 | $3,860,800.00 | 203,200 | 2019-02-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.51 | 3,625 | $9,094.40 | 106,015 | 2026-09-04 | Filing | |
| $2.67 | 5,165 | $13,767.31 | 109,640 | 2026-09-03 | Filing | |
| $2.75 | 656 | $1,804.00 | 114,805 | 2026-09-02 | Filing | |
| $2.66 | 29,251 | $77,948.06 | 350,649 | 2026-09-03 | Filing | |
| $2.66 | 72,606 | $193,473.21 | 2,294,600 | 2026-09-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,477,460 | $4,584,225 | 0% | |
| 2. | 1,461,163 | $2,703,152 | 0% | |
| 3. | 1,068,063 | $1,975,917 | 0% | |
| 4. | 251,966 | $466,137 | 0% | |
| 5. | 139,900 | $258,815 | 0% |
News See All
Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab
Alector Inc. (NASDAQ:ALEC) is one of the best stocks under $3 to invest in.
10 Best Stocks Under $3 to Invest In
On October 16, Victoria Greene, Chief Investment Officer of G Squared Private Wealth Management, appeared on CNBC to state that small caps demonstrate lasting strength.
Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation
Alector Inc. (NASDAQ:ALEC) is one of the stocks under $10 to buy now. On July 28, Mizuho upgraded Alector from Neutral to Outperform, while raising the price target from $2.50 to $3.50.
10 Stocks Under $10 to Buy Now
Earlier on July 1, Peter Kraus, Aperture Investors chairman and CEO, joined 'Squawk Box' on CNBC to suggest that the small and mid-cap area is a place for significant growth.
Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript February 27, 2024 Alector, Inc. beats earnings expectations. Reported EPS is $-0.49, expectations were $-0.8. Alector, Inc.
Alector, Inc. (NASDAQ:ALEC) Q2 2023 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC) Q2 2023 Earnings Call Transcript August 4, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Alector Midyear 2023 Earnings Conference Call.
Hedge Fund Resource Center